FDA expands Anktiva approval to include papillary-only bladder cancer

Go back to FDA expands Anktiva approval to include papillary-only bladder cancer
(NASDAQ: IBRX) Delayed: 8.64 --0 (-0%)
Previous Close $8.64    52 Week High $ 
Open $8.64    52 Week Low $ 
Day High $8.64    P/E N/A 
Day Low $8.64    EPS $ 
Volume 3,064